Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

The North Texas Region of the Red Cross operates two fixed donation sites in the area: the Irving Blood and Platelet Donation ...

Shares of WORK Medical are rising Monday after the company received manufacturing approval for one of its AI-powered products ...

The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including ...

Research has proven frozen blood platelets are safe and effective for use in critically injured patients—a breakthrough dramatically extending their shelf life for transfusions from one week to two ...

FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today ...